Charles River Laboratories Intl. (CRL) Sets New 1-Year High at $141.94

Charles River Laboratories Intl. Inc (NYSE:CRL) hit a new 52-week high on Tuesday . The company traded as high as $141.94 and last traded at $141.13, with a volume of 432280 shares. The stock had previously closed at $140.86.

CRL has been the topic of a number of recent analyst reports. Barclays reiterated a “hold” rating and set a $135.00 price target on shares of Charles River Laboratories Intl. in a report on Thursday, February 14th. SunTrust Banks increased their price target on shares of Charles River Laboratories Intl. to $151.00 and gave the company a “buy” rating in a report on Thursday, February 14th. Zacks Investment Research upgraded shares of Charles River Laboratories Intl. from a “sell” rating to a “hold” rating and set a $156.00 price target on the stock in a report on Thursday, February 14th. Jefferies Financial Group reiterated a “buy” rating and set a $162.00 price target on shares of Charles River Laboratories Intl. in a report on Thursday, February 14th. Finally, Morgan Stanley increased their price target on shares of Charles River Laboratories Intl. from $112.00 to $136.00 and gave the company an “equal weight” rating in a report on Monday, December 3rd. Seven research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $140.21.

The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.32 and a current ratio of 1.61. The firm has a market capitalization of $6.77 billion, a PE ratio of 23.41, a P/E/G ratio of 1.83 and a beta of 0.99.

Charles River Laboratories Intl. (NYSE:CRL) last issued its earnings results on Wednesday, February 13th. The medical research company reported $1.49 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.39 by $0.10. Charles River Laboratories Intl. had a net margin of 9.99% and a return on equity of 24.09%. The company had revenue of $605.53 million for the quarter, compared to analysts’ expectations of $589.86 million. During the same quarter last year, the company posted $1.40 earnings per share. The firm’s quarterly revenue was up 26.5% on a year-over-year basis. On average, analysts forecast that Charles River Laboratories Intl. Inc will post 6.32 earnings per share for the current fiscal year.

In related news, Chairman James C. Foster sold 1,977 shares of the firm’s stock in a transaction that occurred on Monday, December 10th. The shares were sold at an average price of $129.11, for a total value of $255,250.47. Following the sale, the chairman now owns 267,676 shares in the company, valued at $34,559,648.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Robert J. Bertolini sold 3,440 shares of the firm’s stock in a transaction that occurred on Tuesday, December 4th. The stock was sold at an average price of $133.77, for a total transaction of $460,168.80. Following the completion of the sale, the director now owns 29,876 shares in the company, valued at approximately $3,996,512.52. The disclosure for this sale can be found here. Insiders sold 30,417 shares of company stock worth $3,590,419 in the last 90 days. 2.10% of the stock is currently owned by corporate insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Fort L.P. bought a new position in Charles River Laboratories Intl. in the fourth quarter worth approximately $27,000. Riverview Trust Co bought a new position in Charles River Laboratories Intl. in the fourth quarter worth approximately $30,000. Kwmg LLC raised its position in Charles River Laboratories Intl. by 32.4% in the fourth quarter. Kwmg LLC now owns 429 shares of the medical research company’s stock worth $49,000 after acquiring an additional 105 shares during the period. Captrust Financial Advisors raised its position in Charles River Laboratories Intl. by 101.3% in the fourth quarter. Captrust Financial Advisors now owns 612 shares of the medical research company’s stock worth $69,000 after acquiring an additional 308 shares during the period. Finally, Csenge Advisory Group bought a new position in Charles River Laboratories Intl. in the third quarter worth approximately $91,000. Institutional investors and hedge funds own 99.47% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Charles River Laboratories Intl. (CRL) Sets New 1-Year High at $141.94” was reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this article on another website, it was illegally copied and republished in violation of international copyright and trademark laws. The original version of this article can be viewed at https://www.chaffeybreeze.com/2019/02/19/charles-river-laboratories-intl-crl-sets-new-1-year-high-at-141-94.html.

Charles River Laboratories Intl. Company Profile (NYSE:CRL)

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Recommended Story: Bollinger Bands

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply